Literature DB >> 33895856

Low technology, mild controlled hypothermia for necrotizing enterocolitis treatment: an initiative to improve healthcare to preterm neonates.

Walusa Assad Gonçalves-Ferri1, Cristina Helena Faleiros Ferreira2, Laryssa de Carli de Almeida Couto3, Thaissa Rodrigues Souza2, Thayane de Castro Peres2, Fabio Carmona2, Davi Casale Aragon2, Gerson Crott2, Marisa M Mussi-Pinhata2, Jose Simon Camelo Junior2, Anelise Roosch2, Lourenço Sbragia Neto3.   

Abstract

Necrotizing enterocolitis (NEC) treatment remains unchanged for years. Data suggest that mild controlled hypothermia could potentially improve NEC outcomes. Our units presented unfavourable outcomes on NEC. The aim was to assess our experience with low technology, mild controlled hypothermia on NEC outcomes, and improve preterm infants' healthcare. This was a single-center quality improvement study with retrospective cohort design at the neonatal intensive care unit in the university hospital. Forty-three preterm infants with NEC (Modified Bell's Stage II/III) were included: 19 in the control group (2015-2018) and 24 in the hypothermia group (2018-2020). The control group received standard treatment (fasting, abdominal decompression, and broad-spectrum antibiotics). The hypothermia group underwent cooling to 35.5 °C for 48 h after NEC diagnosis, along with conventional treatment. The primary outcomes are intestinal perforation, need for surgery, duration of parenteral nutrition, death, and extensive resection of the small intestine. There was no statistical difference in the NEC score. The hypothermia group required less surgery (aRR 0.40; 95% CI 0.19-0.85), presented less bowel perforation (aRR 0.39; 95% CI 0.18; 0.83), had a shorter duration of parenteral nutrition (aHR 5.28; 95% CI 1.88-14.89), did not need extensive intestinal resection, (0 vs 15.7%), and did not experience any deaths (0 vs 31.6%).Conclusions: In our experience, low technology, mild controlled hypothermia was feasible, not related to adverse effects, and effective treatment for NEC Modified Bell's Stage II/III. It avoided surgery, bowel perforation, and extensive intestinal resection; reduced mortality; and shortened parenteral nutrition duration. What is Known: • New approaches have been proposed to avoid enterocolitis incidence; however, the treatment of enterocolitis stage 2 has been the same for decades, and unfavourable outcomes remain despite conventional management. • Studies suggest that hypothermia can be an alternative to enterocolitis treatment. What is New: • Mild controlled hypothermia can be an additional practice to treat enterocolitis stage 2, is feasible, and is not related to adverse effects to preterm infants. • It can decrease surgery needs, duration of parenteral nutrition, and death and avoids extensive intestinal resection in preterm infants.

Entities:  

Keywords:  Hypothermia; Necrotizing enterocolitis; Preterm infant; Small intestine

Year:  2021        PMID: 33895856     DOI: 10.1007/s00431-021-04014-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  35 in total

1.  Incidence and timing of presentation of necrotizing enterocolitis in preterm infants.

Authors:  Wendy H Yee; Amuchou Singh Soraisham; Vibhuti S Shah; Khalid Aziz; Woojin Yoon; Shoo K Lee
Journal:  Pediatrics       Date:  2012-01-23       Impact factor: 7.124

2.  Quality Improvement Initiative to Reduce the Necrotizing Enterocolitis Rate in Premature Infants.

Authors:  Maria M Talavera; Gary Bixler; Corin Cozzi; James Dail; Randy R Miller; Richard McClead; Kristina Reber
Journal:  Pediatrics       Date:  2016-05       Impact factor: 7.124

3.  Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants.

Authors:  Vaidyanathan Ganapathy; Joel W Hay; Jae H Kim
Journal:  Breastfeed Med       Date:  2011-06-30       Impact factor: 1.817

Review 4.  Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis.

Authors:  Clare M Rees; Agostino Pierro; Simon Eaton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-09-19       Impact factor: 5.747

5.  Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study.

Authors:  Barbara B Warner; Elena Deych; Yanjiao Zhou; Carla Hall-Moore; George M Weinstock; Erica Sodergren; Nurmohammad Shaikh; Julie A Hoffmann; Laura A Linneman; Aaron Hamvas; Geetika Khanna; Lucina C Rouggly-Nickless; I Malick Ndao; Berkley A Shands; Marilyn Escobedo; Janice E Sullivan; Paula G Radmacher; William D Shannon; Phillip I Tarr
Journal:  Lancet       Date:  2016-03-09       Impact factor: 79.321

Review 6.  Necrotizing enterocolitis.

Authors:  Josef Neu; W Allan Walker
Journal:  N Engl J Med       Date:  2011-01-20       Impact factor: 91.245

7.  National prospective surveillance study of necrotizing enterocolitis in neonatal intensive care units.

Authors:  Clare M Rees; Simon Eaton; Agostino Pierro
Journal:  J Pediatr Surg       Date:  2010-07       Impact factor: 2.545

8.  Variations in incidence of necrotizing enterocolitis in Canadian neonatal intensive care units.

Authors:  Koravangattu Sankaran; Barbara Puckett; David S C Lee; Mary Seshia; Jill Boulton; Zhenguo Qiu; Shoo K Lee
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-10       Impact factor: 2.839

9.  State-based analysis of necrotizing enterocolitis outcomes.

Authors:  Yigit S Guner; Philippe Friedlich; Choo Phei Wee; Fred Dorey; Victoria Camerini; Jeffrey S Upperman
Journal:  J Surg Res       Date:  2008-12-04       Impact factor: 2.192

10.  Preventive strategies and factors associated with surgically treated necrotising enterocolitis in extremely preterm infants: an international unit survey linked with retrospective cohort data analysis.

Authors:  Mark Adams; Dirk Bassler; Brian A Darlow; Kei Lui; Brian Reichman; Stellan Hakansson; Mikael Norman; Shoo K Lee; Kjell K Helenius; Liisa Lehtonen; Laura San Feliciano; Maximo Vento; Marco Moroni; Marc Beltempo; Junmin Yang; Prakesh S Shah
Journal:  BMJ Open       Date:  2019-10-14       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.